Skip to main content
OpenTrials
Completed

NCT Number: NCT05705518

Artificial Tears, Tear Lipids and Tear Film Dynamics

Dry eye disease (DED) is pervasive with some reports estimating over 16 million adults diagnosed in the United States. Currently, artificial tears remain an integral part of managing dry eyes and are mainly used for symptomatic relief. Recent studies have shown there may be therapeutic benefits with regular use of lipid-based artificial tears to improve the structure of the tear film, which may improve tear film stability and provide relief of symptoms. In this study the investigators propose to compare effects on the tear lipid film and its dynamics between 3 lipid based artificial tears and a widely available non-lipid based artificial tear.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Clinical Research Center, School of Optometry, University of California, Berkeley

Berkeley, California, 94720-2020, United States

About this study

This is a prospective, double-masked, randomized, controlled, parallel-group trial designed to compare the impact of Systane Complete PF lipid-based artificial tears (the Treatment solution under study) on tear lipid layer thickness compared with a non-lipid Control solution, Refresh Relieva PF. Secondarily, the study will compare changes in tear lipid layer thickness, lipid layer uniformity, tear film thinning dynamics, and symptoms between the Treatment solution, the non-lipid Control solution, and 2 other available lipid-based solutions (Active Comparators: Refresh Optive Mega-3 PF and CVS Health Lubricant Eye Drop (PG 0.6%)). The study will include 4 clinic visits, and require 1 week of single-masked run-in with Systane Ultra PF (an over-the-counter non-lipid-based solution) followed by 3 months of study treatment dosing. All subjects will complete a screening interview, then an in-clinic baseline ocular health examination and study eligibility determination followed by dispensing of the Control solution to all subjects for 1 week of run-in. After that week, subjects will be randomized to 1 of the 4 artificial tear solutions and have an in-clinic ocular examination and dispense of the assigned solution to use for 3 months. An in-clinic follow-up examination is completed after 1 month of study solution use, followed by a phone interview at 2 months, and a final in-clinic examination at 3 months post-dispensing.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Best Corrected Visual Acuity of 20/30 or better;
  • Experiencing Dry Eye symptoms (baseline OSDI score >= 13);

Exclusion criteria

  • Currently experiencing active ocular inflammation or infection;
  • Currently using topical eye medication (not including over-the-counter eyedrops);
  • Having systemic health conditions or using prescription medications (including but not limited to isotretinoin derivatives) that could alter tear film physiology;
  • Having a history of severe ocular trauma, ocular surgery, or diabetes;
  • Being pregnant or breast feeding;
  • Being a current contact lens wearer;
  • Currently having a condition or being in a situation which, in the examiner's opinion, may put the subject at significant risk, may confound the study results, or may otherwise significantly interfere with their participation in the study;

Treatment and study plan

Systane Complete PF

Drug

3 month use, 4 times daily, of Systane Complete PF, a lipid-based, preservative-free artificial tear product

Refresh Relieva PF

Drug

3 month use, 4 times daily, of Refresh Relieva PF, a non-lipid-based, preservative-free artificial tear product

Refresh Optive Mega-3 PF

Drug

3 month use, 4 times daily, of Refresh Optive Mega-3 PF, a lipid-based, preservative-free artificial tear product

CVS Health Lubricant Eye Drop (PG 0.6%)

Drug

3 month use, 4 times daily, of CVS Health Lubricant Eye Drop (PG 0.6%), a lipid-based, preserved artificial tear product

Primary outcomes

  1. Tear Lipid Layer Thickness

    Time frame: Lipid Layer Thickness measured once at post-run-in baseline and once at 3mo follow-up visit

    Change in Tear Lipid Layer Thickness (3mo follow-up - post-run-in baseline)

Secondary outcomes

  1. Tear Lipid Layer Uniformity

    Time frame: Lipid Layer Uniformity measured once at post-run-in baseline and once at 3mo follow-up visit

    Change (3mo follow-up - post-run-in baseline) in Tear Lipid Layer Thickness Coefficient of Variation (CV). The CV is calculated as the standard deviation divided by the mean lipid layer thickness. A greater value of the CV indicates more variability in lipid layer thickness, a smaller value of the CV indicates a more uniformly thick lipid layer.

  2. Tear Film Thinning Rate

    Time frame: Tear Film Thinning Rate measured once at post-run-in baseline and once at 3mo follow-up visit

    Change in Tear Film Thinning rate (3mo follow-up - post-run-in baseline)

Other outcomes

  1. Exploratory - Subjective Symptoms - OSDI Questionnaire

    Time frame: OSDI questionnaire administered once at post-run-in baseline and once at 3mo follow-up visit

    Change (3mo follow-up - post-run-in baseline) in Ocular Surface Disease Index (OSDI) score. The OSDI questionnaire score ranges from 0-100, with higher scores indicating more severe symptoms of Dry Eye Disease.

  2. Exploratory - Subjective Symptoms - SANDE

    Time frame: SANDE questionnaire administered once at post-run-in baseline and once at 3mo follow-up visit

    Change in Symptom Assessment questionnaire iN Dry Eye (SANDE) score (3mo follow-up - post-run-in baseline)

  3. Exploratory - Subjective Symptoms - DEQ-5

    Time frame: DEQ-5 questionnaire administered once at post-run-in baseline and once at 3mo follow-up visit

    Change in 5-Item Dry Eye Questionnaire (DEQ-5) score (3mo follow-up - post-run-in baseline)

Sponsors and collaborators

Lead sponsor

University of California, Berkeley

Other

Collaborators

  • Alcon Research

Registry information

Official study title

Effects Of Artificial Tears on Tear Lipid Films and Tear Film Dynamics In Vivo

Acronym: AlconAT

Important dates

Study start
2023
Primary completion
2023
Study completion
2024
First posted
Jan 30, 2023
Registry last updated
Mar 14, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.